PUNE, India, August 26, 2018 /ResearchByMarkets/— Bone Marrow Transplant Rejection – Pipeline Review, H2 2018, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.
Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.
REQUEST SAMPLE PAGES FOR THIS REPORT:
Bone Marrow Transplant Rejection – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 8, 30, 11, 1, 43, 7 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.
Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
– The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AbGenomics International Inc
apceth Biopharma GmbH
Aptevo Therapeutics Inc
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cell Source Inc
Cell2B Advanced Therapeutics SA
Cellect Biotechnology Ltd
Cellective BioTherapy Inc
Cynata Therapeutics Ltd
Elsalys Biotech SA
Enlivex Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Generon (Shanghai) Corp Ltd
Heat Biologics Inc
Heidelberg Pharma AG
Inspyr Therapeutics Inc
Jazz Pharmaceuticals Plc
Johnson & Johnson
Kadmon Corp LLC
Kiadis Pharma NV
LG Chem Ltd
Magenta Therapeutics Inc
Medicenna Therapeutics Corp
Millennium Pharmaceuticals Inc
Pharmicell Co Ltd
Pluristem Therapeutics Inc
Seattle Genetics Inc
Seres Therapeutics Inc
Sublimity Therapeutics Ltd
Syndax Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
United BioPharma Inc
Vault Pharma Inc
VBI Vaccines Inc
Zai Lab Ltd
Get in touch with us:
Ritesh Tiwari, Director